- Fisher & Paykel Healthcare disclosed its FY21 trading update with 446% growth in its hospital hardware.
- Arvida Group’s annual meeting would take place on 2 July, which would see a change in its management.
- Promisia Healthcare announced the allotment of new equity.
The outburst of the coronavirus pandemic has had a colossal impact on our lives. Other than affecting our health, COVID-19 has massively hit our work, livelihood, social environment as well as the economy on the whole.
With the increased need for medicines and hospitalisation for people fighting the deadly virus, the healthcare sector has come up to the rescue of affected ones and is working tirelessly 24X7 to keep COVID-19 at bay. This has given hopes to countries worldwide that soon the day would come when this novel coronavirus would be eliminated and people would again lead a normal life.
Source: © Jirsak | Megapixl.com
Here in this article, let us explore the 4 NZX healthcare stocks which are alluring the investors.
Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare Corporation Limited (NZX:FPH; ASX:FPH) in its update on trading activities stated that its hospital hardware sales continued to surge owing to the increased hospitalisation rates amid the current pandemic.
Operating revenue for the Company was up 73% on pcp for the period of 9 months ended 31 December 2020. Furthermore, FPH witnessed that its hospital hardware rose 446% and hospital consumables grew 54% during the said period.
Also, with the prevailing market uncertainties, the Company cannot provide the exact full-year guidance for FY21, however, it is confident that its revenue and NPAT for FY21 would be higher than the previous assumptions.
On 30 April, Fisher & Paykel Healthcare Corporation ended the day's trading session down by 1.40% at NZ$35.950.
Arvida Group Limited
Arvida Group Limited (NZX:ARV) announced today that its Annual Meeting of the shareholders would take place on 2 July 2021.
As per the Company’s policies, both its independent directors, Susan Paterson and Susan Petersen, would retire from their positions and would be eligible for re-election at the annual meeting. Also, the Annual Meeting would witness ARV's chair Peter Wilson seeking retirement and Anthony Beverley stepping in as the Chair.
Moreover, Arvida Group has started accepting nominations for the post of directors, the closing date of which is 14 May 2021.
On 30 April, Arvida Group ended the day's trading session at NZ$1.800.
Rua Bioscience Limited
Rua Bioscience Limited (NZX:RUA) has recently announced the appointment of Dr Andrea Grant as the Company’s Chief Commercial Officer (CCO) and he will assume the charge on 7 June 2021.
Grant comes with a 20-year of experience in the pharmaceutical and biotech industries across the globe.
On 30 April, Rua Bioscience ended the day's trading session at NZ$0.400.
Promisia Healthcare Limited
Promisia Healthcare Limited (NZX:PHL) had declared an update on its share purchase plan (SPP), thereby successfully raising around NZ$1.7 million.
This would provide the Company with sufficient working capital and would considerably help in future growth and developments.
Also, Promisia Healthcare had issued new shares worth $450,000 at an issue price of $0.001 per share to its various wholesale investors
As per the special meeting of the shareholders on 24 March 2021, the Company’s management has agreed to issue the remaining capitalisation shares to the trustees of the Brankin Family Interest Trust.
On 30 April, Promisia Healthcare ended the day's trading session up by 100.00% at NZ$0.002.